BioNTech SE (NASDAQ:BNTX) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lowered its position in BioNTech SE (NASDAQ:BNTX) by 33.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,533 shares of the company’s stock after selling 21,125 shares during the period. Vontobel Holding Ltd.’s holdings in BioNTech were worth $4,383,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. State of Wyoming acquired a new position in shares of BioNTech during the 2nd quarter worth about $26,000. Covestor Ltd acquired a new position in shares of BioNTech during the 3rd quarter worth about $32,000. Eagle Bay Advisors LLC acquired a new position in shares of BioNTech during the 2nd quarter worth about $33,000. Resurgent Financial Advisors LLC acquired a new position in shares of BioNTech during the 4th quarter worth about $47,000. Finally, UMB Bank n.a. acquired a new position in shares of BioNTech during the 4th quarter worth about $50,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX stock opened at $86.40 on Thursday. The firm’s 50 day moving average price is $91.49 and its 200-day moving average price is $97.57. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. BioNTech SE has a one year low of $85.21 and a one year high of $125.83. The firm has a market cap of $20.54 billion, a P/E ratio of 20.97 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. As a group, equities research analysts predict that BioNTech SE will post -1.67 EPS for the current year.

Analysts Set New Price Targets

BNTX has been the subject of several research analyst reports. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. The Goldman Sachs Group reduced their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. UBS Group dropped their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. Oppenheimer started coverage on shares of BioNTech in a research note on Friday, January 5th. They set a “market perform” rating for the company. Finally, BMO Capital Markets dropped their price objective on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research note on Thursday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.